Carlos Malvestutto

Associate Professor

The Ohio State University Wexner Medical Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Carlos Malvestutto is an Associate Professor at The Ohio State University Wexner Medical Center in the United States. His research focuses on cardiovascular health in individuals with HIV, investigating the effects of various antiretroviral therapies and other risk factors. Recent publications highlight topics such as the impact of statins on cardiovascular events, as well as the relationship between cytokines and physical function in HIV-positive populations.

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Collaborators (9)

Félix Gutiérrez

Professor of Medicine

Universidad Miguel Hernández de Elche

SPAIN

View details

Nwora Lance Okeke

Duke University Medical Center

UNITED STATES

View details

Sabina Haberlen

Johns Hopkins University

UNITED STATES

View details

Gerald Bloomfield

Duke University

UNITED STATES

View details

Judith Currier

Professor

University of California, Los Angeles

UNITED STATES

View details

Abhishek Niroula

Assistant Professor

University of Gothenburg

SWEDEN

View details

Edgar Overton

The University of Alabama

UNITED STATES

View details

Maheen Abidi

University of Colorado Boulder

UNITED STATES

View details

Jacqueline Flynn

Thomas Jefferson University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Carlos Malvestutto

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV

Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort

Cytomegalovirus IgG is Associated With Physical Function But Not Muscle Density in People With HIV

Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial

Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV

Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial

Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)

Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV

Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV)

ART and cardiovascular-disease risk in people with HIV

COVID-19 Vaccination Rates in a Global HIV Cohort

Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus

Associations Between HIV Serostatus and Cardiac Structure and Function Evaluated by 2‐Dimensional Echocardiography in the Multicenter AIDS Cohort Study

Collaborators (9)

Félix Gutiérrez

Nwora Lance Okeke

Sabina Haberlen

Gerald Bloomfield

Judith Currier

Abhishek Niroula

Edgar Overton

Maheen Abidi

Jacqueline Flynn

Make your next move.